---
title: "Cerenome | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 411 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295992521.md"
datetime: "2026-08-15T05:41:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295992521.md)
  - [en](https://longbridge.com/en/news/295992521.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295992521.md)
generator: "portal-rs"
---

# Cerenome | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 411 K

Revenue: As of FY2026 Q2, the actual value is USD 411 K, missing the estimate of USD 1.11 M.

EPS: As of FY2026 Q2, the actual value is USD -1.31.

EBIT: As of FY2026 Q2, the actual value is USD -9.108 M.

#### Financial Position

Cerenome, Inc. reported cash, cash equivalents, and investments of $8.6 million as of June 30, 2026, which was the same amount reported on December 31, 2025. Specifically, cash and cash equivalents were $2,366 thousand on June 30, 2026, and $4,256 thousand on December 31, 2025. Investments were $6,221 thousand on June 30, 2026, and $4,356 thousand on December 31, 2025. Total assets were $14,030 thousand as of June 30, 2026, a decrease from $16,325 thousand as of December 31, 2025. Total liabilities were $8,567 thousand as of June 30, 2026, down from $12,329 thousand as of December 31, 2025. Total stockholders’ equity increased to $5,463 thousand as of June 30, 2026, from $3,996 thousand as of December 31, 2025.

#### Revenue

Grant revenue for the second quarter of 2026 was $411 thousand, a decrease from $1,390 thousand for the second quarter of 2025. For the six months ended June 30, grant revenue was $1,439 thousand in 2026, compared to $2,449 thousand in 2025.

#### Operating Performance

Cerenome, Inc. reported an operating loss of - $9,057 thousand for the second quarter of 2026, which was higher than the operating loss of - $1,538 thousand for the second quarter of 2025. The operating loss for the first six months of 2026 was - $16,176 thousand, compared to - $5,074 thousand for the same period in 2025. The net loss for the second quarter of 2026 was - $9,006 thousand, a decline from a net income of $5,151 thousand in the second quarter of 2025. The net loss for the six months ended June 30, 2026, was - $15,952 thousand, compared to - $12,250 thousand for the same period in 2025.

#### Operating Expenses

Total operating expenses for the second quarter of 2026 were $9,468 thousand, an increase from $2,928 thousand in the second quarter of 2025. Research and development expenses increased to $4,265 thousand in Q2 2026 from $1,246 thousand in Q2 2025. General and administrative expenses rose to $5,203 thousand in Q2 2026 from $1,682 thousand in Q2 2025. For the six months ended June 30, 2026, total operating expenses were $17,615 thousand, compared to $7,523 thousand in 2025.

#### Cash Flow Activities

Net cash used in operating activities for the six months ended June 30, 2026, was - $13,370 thousand, an increase from - $11,970 thousand for the same period in 2025. Net cash used in investing activities was - $3,167 thousand in 2026, compared to - $1,074 thousand in 2025. Net cash provided by financing activities was $10,145 thousand in 2026, down from $15,201 thousand in 2025.

#### Operational Metrics

During the first half of 2026, Cerenome, Inc. performed 232 CNSide cerebrospinal fluid tests. The company achieved its 2026 corporate objective for contracted commercial payer coverage, reaching 150 million covered lives by mid-year. Cerenome also received a Medicare Provider Transaction Access Number and a dedicated American Medical Association billing identifier for CNSide.

#### Outlook for 2026

Cerenome, Inc. affirmed its 2026 milestones, which include defining the optimal dose for REYOBIQ in Leptomeningeal Metastases and completing enrollment in the ReSPECT-GBM Phase 2 trial, with data expected in Q1 2027. The company also aims to expand U.S. commercial payer coverage beyond 150 million covered lives and secure Medicare coverage for CNSide. Additionally, Cerenome targets an annualized run-rate of test orders exceeding 1,250.

### Related Stocks

- [CNSY.US](https://longbridge.com/en/quote/CNSY.US.md)

## Related News & Research

- [Plus Therapeutics amends bylaws to reflect corporate name change to Cerenome](https://longbridge.com/en/news/294876172.md)
- [Plus Therapeutics Q2 FY26 net loss widens to $9.01 million; operating loss widens to $9.06 million](https://longbridge.com/en/news/295971223.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**